Providence First Trust’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-12,602
Closed -$321K 182
2025
Q3
$321K Sell
12,602
-940
-7% -$23.2K 0.11% 96
2025
Q2
$328K Hold
13,542
0.12% 97
2025
Q1
$343K Sell
13,542
-595
-4% -$15.6K 0.14% 88
2024
Q4
$375K Hold
14,137
0.14% 87
2024
Q3
$409K Buy
14,137
+300
+2% +$8.75K 0.17% 71
2024
Q2
$387K Hold
13,837
0.17% 78
2024
Q1
$384K Buy
13,837
+3,899
+39% +$108K 0.17% 85
2023
Q4
$286K Hold
9,938
0.14% 82
2023
Q3
$330K Hold
9,938
0.18% 75
2023
Q2
$365K Sell
9,938
-80
-0.8% -$3.11K 0.2% 72
2023
Q1
$409K Hold
10,018
0.24% 76
2022
Q4
$513K Sell
10,018
-121
-1% -$5.8K 0.3% 71
2022
Q3
$444K Sell
10,139
-2,286
-18% -$111K 0.27% 70
2022
Q2
$651K Hold
12,425
0.37% 66
2022
Q1
$643K Buy
+12,425
New +$645K 0.31% 68

Other funds holding PFE

Providence First Trust's PFE Position: Q4 2025 in Review

Providence First Trust sold out of Pfizer (PFE) in Q4 2025, closing a stake of 12,602 shares — an estimated $321K sold.

Providence First Trust first reported a position in PFE in Q1 2022 and held it in 15 quarters. The position peaked at $651K in Q2 2022. 2,915 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Providence First Trust reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
  • Providence First Trust sold 12,602 Pfizer shares in Q4 2025, an estimated $321K.
  • Providence First Trust first reported a position in Pfizer in Q1 2022 and held it in 15 quarters.
  • Providence First Trust's Pfizer position peaked at $651K in Q2 2022.
  • 2,915 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Providence First Trust's 13F filing for Q4 2025, filed 3 Feb 2026.